Zura Bio Limited
NASDAQ:ZURABiotechnology
+$0.07 today
- Market cap
- $92.96M
- Beta
- 0.03
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.67
Volume 3.02M
Average 0.75M
Returns on capital
Zura Bio Limited management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-67.6%
avg -23.7%
ROIC
-74.1%
avg 264.4%
ROA
-60.2%
avg -126.5%
Analysis
ROA is currently the strongest return metric at -60.2% versus its period average of -126.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Kimberly Ann Davis | Chief Operating Officer, Chief Legal Officer & Corporate Secretary | USD 807.2K | 58 | — | — |
Kiran Nistala MBBS | Chief Medical Officer & Head of Development | USD 691.15K | 53 | — | — |
Sandeep Chidambar Kulkarni | Co-Founder, CEO & Director | USD 55.55K | 45 | 894.00K | 1.37% |
Gary Whale | Chief Technology Officer | — | 52 | 263.00K | 0.40% |
Marlyn Mathew | VP of Finance & Accounting and Principal Financial & Accounting Officer | — | 42 | — | — |
Theresa Lowry | Chief Human Resources Officer | — | 52 | — | — |
Muzammil Mustufa | Chief Business Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Apr 1, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$12.50M
Sells
0
$0.00
Net Transaction Value
+$12.50M
Net buying
Most Active
AI Biotechnology LLC
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Feb 26, 26Feb 26, 2026 | AI Biotechnology LLC Direct | Buy | $12.5M$12,500,000.00 |
Summary
Insiders reported 1 buys worth $12.50M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $12.50M. AI Biotechnology LLC was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Zura Bio Limited compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about ZURA's management, answered from reported figures.
Who manages ZURA?
Zura Bio Limited (ZURA) lists 7 active executives. The top listed executive is Gary Whale, Chief Technology Officer.
Are ZURA insiders buying or selling?
Recent insider activity shows net buying of $56.40M.
Continue the stock analysis
Jump to another research area for this company.